WO2014038524A1 - 乳癌の判定方法 - Google Patents
乳癌の判定方法 Download PDFInfo
- Publication number
- WO2014038524A1 WO2014038524A1 PCT/JP2013/073594 JP2013073594W WO2014038524A1 WO 2014038524 A1 WO2014038524 A1 WO 2014038524A1 JP 2013073594 W JP2013073594 W JP 2013073594W WO 2014038524 A1 WO2014038524 A1 WO 2014038524A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- carbonic anhydrase
- cancer marker
- detecting
- present
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/30—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving catalase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/365—Breast disorders, e.g. mastalgia, mastitits, Paget's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a novel breast cancer marker, a method for detecting it and determining (diagnosis / testing) breast cancer based on the result, and a kit used for the determination.
- diagnosis by detecting a breast cancer marker in a sample such as body fluid or blood, or diagnosis by mammography is performed.
- the amount in a sample is measured using a diagnostic kit or the like using carcinoembryonic antigen (CEA) as a marker, and breast cancer is diagnosed based on the result. is doing.
- CEA carcinoembryonic antigen
- Patent Document 1 Japanese Patent Application Laid-Open No. 2002-131322 identifies a patient having breast cancer or pre-mammary cancer by using a subject's milk duct fluid as a sample and detecting a component in the breast duct fluid. A method is disclosed.
- this document describes a large number of marker candidates including extracellular matrix proteins and apolipoproteins, it merely lists the marker candidates and does not analyze the components in the breast duct fluid of breast cancer patients. Therefore, it is unclear from the disclosure of Patent Document 1 whether the many listed markers are really useful as breast cancer markers.
- Patent Document 2 a tissue piece of a breast cancer patient is analyzed by LC-ESI-MS / MS (liquid chromatography-electrospray ionization-tandem mass spectrometry), and PDX1 (peroxy It describes that redoxin 1) was selected as a breast cancer marker candidate and that PXD1 was detected in the serum of breast cancer patients. There is also a description suggesting that breast cancer is diagnosed by the combined use of PDX1 and other markers. However, there is no disclosure of evidence indicating that these markers are specific for breast cancer, such as measurement results of these markers in samples from non-breast cancer patients. Therefore, it has not been confirmed whether PDX1 is useful as a breast cancer marker and whether a combination with other markers can be used for diagnosis of breast cancer.
- breast cancer diagnostic methods using mammography often have mental and physical distress for the examinee (subject).
- it is difficult to image a young group with high breast density it is still not a highly accurate breast cancer diagnostic technique.
- the conventional breast cancer diagnosis methods have the above-mentioned problems, so the breast cancer screening rate does not improve, the diagnosis of early breast cancer and breast cancer is delayed, and as a result results in the prevention of breast cancer morbidity and breast cancer mortality. It is a big social problem. In order to solve these problems, development of a new breast cancer diagnosis technique using a breast cancer marker protein that is less invasive and highly accurate as an index for breast cancer diagnosis is awaited.
- An object of the present invention is to provide a novel breast cancer marker useful for the detection of breast cancer and a highly accurate novel method for determining breast cancer by detecting the breast cancer marker.
- the present invention has been made for the purpose of solving the above-described problems, and has the following configuration.
- Carboxypeptidase N subunit 2 extracellular matrix protein 1, serum amyloid P component, nebulin, complement component C8 ⁇ chain, apolipoprotein L1, flavin reductase, catalase, carbonic anhydrase 2 (carbonic anhydrase 2), Apolipoprotein CI, nuclear pore glycoprotein 210, superoxide dismutase [Cu-Zn] (superoxide dismutase [Cu-Zn]), bisphosphoglycerate mutase, carbonic anhydrase 1 (carbonic anhydride)
- a breast cancer marker selected from the group consisting of lyase 1) and peroxiredoxin 2.
- Carboxypeptidase N subunit 2 in the sample extracellular matrix protein 1, serum amyloid P component, nebulin, complement component C8 ⁇ chain, apolipoprotein L1, flavin reductase, catalase, carbonic anhydrase 2 (carbonic anhydrase) 2) Apolipoprotein CI, nuclear pore glycoprotein 210, superoxide dismutase [Cu-Zn] (superoxide disproportionase [Cu-Zn]), bisphosphoglycerate mutase, carbonic anhydrase 1 ( A method for determining breast cancer, wherein one or more breast cancer markers arbitrarily selected from the group consisting of carbonic anhydrase 1) and peroxiredoxin 2 are detected and determined based on the results.
- a kit for detecting a breast cancer marker for determining breast cancer comprising a reagent for detecting a breast cancer marker selected from the group consisting of lyase 1) and peroxiredoxin 2.
- the inventors of the present invention are in the midst of intensive research to establish a breast cancer marker with high accuracy of breast cancer diagnosis and a method for determining breast cancer using the same, which has solved the above problems, and information on the breast duct that is the onset site of breast cancer.
- proteomics using nano LC-ESI-MS / MS, the latest two-dimensional liquid chromatography (LC) / mass spectrometry (MS) system, using nipple discharge (Nipple discharge, ND) that can be obtained directly as a sample
- nipple discharge Napple discharge, ND
- a new marker that is expected to be a promising breast cancer marker by comparing the results of nano LC-ESI-MS / MS using nipple discharge derived from breast cancer patients and non-breast cancer patients. Sorted out. And when these markers were used as an index, it was found that breast cancer can be accurately determined, and the present invention was completed.
- the determination method using the breast cancer marker of the present invention enables determination (diagnosis, examination) of breast cancer with higher accuracy.
- the breast cancer marker of the present invention is found, for example, in the nipple secretion, it is possible to determine (diagnose and test) breast cancer noninvasively and simply.
- the results obtained by detecting each protein component in a sample derived from a breast cancer patient and a non-breast cancer patient obtained in Example 1 and the statistical results obtained based thereon are shown, (1) is a carboxypeptidase N subunit 2, (2) shows extracellular matrix protein 1, and (3) shows the results of measuring serum amyloid P component.
- (1) is nebulin
- (2) is a complement.
- (3) shows the results of measuring apolipoprotein L1.
- (1) is flavin reductase
- (2) is Catalase
- (3) show the results of measuring carbonic anhydrase 2 (carbonic anhydrase 2), respectively.
- the results of detecting each protein component in the sample derived from a breast cancer patient and a non-breast cancer patient obtained in Example 1 and the statistical results obtained based on the results are shown.
- (1) is apolipoprotein CI
- ( 2) shows the nuclear pore glycoprotein 210
- (3) shows the result of measurement of superoxide dismutase [Cu-Zn].
- (1) is bisphosphoglycerate mutase
- (2) shows carbonic anhydrase 1 (carbonic anhydrase 1)
- (3) shows the results of measuring peroxiredoxin 2.
- the breast cancer markers of the present invention include carboxypeptidase N subunit 2, extracellular matrix protein 1, serum amyloid P component, nebulin, complement component C8 ⁇ chain, apolipoprotein L1, flavin reductase, catalase, carbonic anhydrase 2 (carbonic ann) Hydrase 2), apolipoprotein CI, nuclear pore glycoprotein 210, superoxide dismutase [Cu-Zn] (superoxide dismutase [Cu-Zn]), bisphosphoglycerate mutase, carbonic anhydrase 1 (carbonic anhydrase 1) and a breast cancer marker selected from the group consisting of peroxiredoxin 2 (hereinafter, these may be collectively referred to as “the breast cancer marker of the present invention”). Although these components are already known per se, it has been revealed for the first time by the present inventors that they are useful as an index for determining breast cancer (breast cancer marker).
- the method for determining breast cancer of the present invention is “a method for determining breast cancer in which the breast cancer marker of the present invention is detected and determined based on the result”.
- the method for detecting the breast cancer marker of the present invention includes a conventional method for detecting and measuring each component which is the breast cancer marker of the present invention.
- a reagent for detecting / measuring a breast cancer marker used therefor any reagent can be used as long as it is a reagent used in a conventional method for detecting / measuring each component of the breast cancer marker.
- Examples of methods for detecting the breast cancer marker of the present invention include, for example, substances having affinity for the breast cancer marker of the present invention (for example, antibodies, lectins, polysaccharides, DNA, enzyme substrates, proteins, various receptors, various ligands, etc. ), So-called enzyme immunoassay (EIA), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), simple immunochromatographic assay, etc. itself
- EIA enzyme immunoassay
- RIA radioimmunoassay
- ELISA enzyme-linked immunosorbent assay
- FFA fluorescence immunoassay
- simple immunochromatographic assay etc. itself
- methods using these in combination with high performance liquid chromatography (HPLC), electrophoresis, capillary electrophoresis, capillary chip electrophoresis and the like can be mentioned.
- Examples of the measurement principle include, but are not limited to, a sandwich method,
- the breast cancer marker of the present invention may be detected by a measurement method according to an immunoagglutination method such as an immunoratio wax method or an immunoturbidimetric method. These detection methods may be performed according to a method known per se.
- an immunoagglutination method such as an immunoratio wax method or an immunoturbidimetric method.
- the antibody against the breast cancer marker used for detecting the breast cancer marker of the present invention is not particularly limited as long as it is an antibody capable of recognizing the breast cancer marker of the present invention, a partial peptide thereof, or a salt thereof.
- any of a polyclonal antibody and a monoclonal antibody may be used, and these may be used alone or in appropriate combination.
- these antibodies may be used as F (ab ′) 2 , Fab ′, or Fab after digestion with an enzyme such as pepsin or papain, if necessary.
- a commercially available antibody against the breast cancer marker of the present invention can also be used.
- Reagents used for detecting the above-described breast cancer marker of the present invention the concentration at the time of detection, the measurement conditions for carrying out the detection, etc. (reaction temperature, reaction time, pH at the time of reaction, measurement wavelength, measurement device, etc.) ) May be set according to the measurement method of the above-described immunological measurement method known per se, and any of the automatic analyzers and spectrophotometers that are usually used in this field are also used. Can be used without exception.
- reagents usually used in this field for example, stabilizers such as buffers, reaction accelerators, sugars, proteins, salts, surfactants, A preservative or the like that does not inhibit the stability of coexisting reagents or the like and does not inhibit the reaction between the breast cancer marker of the present invention and the antibody against the breast cancer marker of the present invention may be included.
- concentration may be appropriately selected from a concentration range usually used in this field.
- a method of detecting a breast cancer marker when the breast cancer marker to be detected is an enzyme, such as a method of reacting this with a coloring reagent to lead to a coloring reaction, and measuring the amount of the resulting dye with a spectrophotometer or the like
- a method known per se can also be mentioned.
- the coloring reagent used for such purposes include coloring reagents usually used in this field, and are appropriately selected for each enzyme to be measured. Also, the concentration used may be appropriately set from the concentration range usually used in this field.
- two or more breast cancer markers of the present invention may be detected in combination.
- the combination may be any combination of two or more of the breast cancer markers of the present invention, and is not particularly limited.
- any combination of one or more breast cancer markers of the present invention and one or more breast cancer markers other than the breast cancer marker of the present invention may be used.
- the detection of the breast cancer marker of the present invention is not limited to the method used, and may be performed by a measurement system using an automatic analyzer.
- an automatic analyzer There are no particular restrictions on the combination of reagents, etc. when performing measurement using a method for use or an automatic analyzer, depending on the environment and model of the automatic analyzer to be applied, or taking other factors into consideration
- the combination of reagents and the like that are considered to be the best may be appropriately selected and used.
- the breast cancer marker of the present invention may be detected by performing protein coverage analysis by so-called nano LC-ESI-MS / MS.
- Nano LC-ESI-MS / MS uses a nano liquid chromatograph as a separation means, sends it at a low flow rate of several hundred nL / min, and separates the components in the sample with a liquid chromatograph for a sample consisting of many components.
- the mass analysis is performed online by electrospray ionization, and the mass component specified by the mass analysis is performed again using collision-induced dissociation.
- this analysis method after mass spectrometry is performed once, only specific mass components are subjected to mass spectrometry again, and the obtained fragment pattern is analyzed, so that more detailed analysis can be performed.
- the LC portion of the nano LC-ESI-MS / MS can be detected by using two separation systems having different pHs, and two-dimensional nano LC-ESI.
- -It may be detected by performing a protein exhaustive analysis by MS / MS.
- a specific example of the method for detecting a breast cancer marker of the present invention by two-dimensional nano LC-ESI-MS / MS is as follows.
- the mobile phase is a basic solution (pH 9 to 10) such as about 20 mM ammonium formate aqueous solution or about 70 mM triethylamine aqueous solution and acetonitrile, and several ⁇ L / min.
- the liquid is fed at a low flow rate (preferably 5 to 500 ⁇ L / min) to separate the components in the sample, and for example, several tens of fractions are collected at regular time intervals of about 1 to 10 minutes.
- a 0.1% aqueous trifluoroacetic acid solution is added to each fraction to dissolve the separated components.
- each total amount of each fraction solution obtained is applied to a second-dimensional liquid chromatograph and separated by the following method. That is, the total amount of each of the above-mentioned fractions was applied to a reversed-phase chromatographic column, and the mobile phase was an acidic solution (pH 2-3) such as 0.1% formic acid aqueous solution, acetonitrile / 0.1 % Formic acid is fed at a low flow rate of several tens to hundreds of nL / min (preferably 50 to 500 nL / min), a large number of components in each fraction are separated, and ESI-MS / MS is performed online.
- an acidic solution pH 2-3
- breast cancer determination is performed by the following method, for example.
- the breast cancer marker of the present invention by detecting the breast cancer marker of the present invention in a sample derived from a subject and detecting that the breast cancer marker is detected, it is possible to determine that the subject has a risk of breast cancer or a high risk of breast cancer. is there. Alternatively, when the breast cancer marker is not detected, it can be determined that the subject has no risk of breast cancer or has a low risk of breast cancer.
- the amount of the breast cancer marker of the present invention contained in the sample is determined by the above method. Then, the result is compared with the result obtained in advance using a sample derived from a non-breast cancer patient as a separate sample in advance, and the amount of the breast cancer marker contained in the sample derived from the subject is included in the sample derived from the non-breast cancer patient. From the test result that the amount is larger than the amount, it is possible to determine that the subject has a risk of breast cancer or a high risk of breast cancer.
- the subject has no risk of breast cancer. It is possible to determine that the risk of breast cancer is low.
- a reference value is set in advance, and from the test result that the amount of the breast cancer marker of the present invention is larger than the reference value of the breast cancer marker, it is determined that the subject has a risk of breast cancer or the subject has a high risk of breast cancer. Is possible.
- a plurality of judgment categories are set corresponding to the amount of the breast cancer marker or its quantitative range [for example, (1) there is no risk of breast cancer, (2) there is a low risk of breast cancer, (3) there are signs of breast cancer It is also possible to determine which determination category the test result is in (4) high risk of breast cancer, etc.].
- the amount of the breast cancer marker of the present invention in the subject-derived sample measured at a certain time point is compared with the amount of the breast cancer marker at a different time point, and whether there is an increase or decrease in the amount of the breast cancer marker. Further, by evaluating the degree of increase / decrease, it is possible to diagnose the degree of progression or malignancy of breast cancer, or postoperative prognosis. That is, from the test result that an increase in the amount of the breast cancer marker was observed, the disease progressed to breast cancer (or the malignancy of breast cancer increased), or there was an indication of progression of the disease state to breast cancer (or breast cancer). Can be determined).
- the pathology of breast cancer has improved or that there is an indication of improvement in the pathology of breast cancer.
- a method of detecting and measuring two or more breast cancer markers of the present invention and determining breast cancer based on the results is also included. For example, by detecting the breast cancer marker of the present invention alone or in combination of two or more, the presence pattern of the breast cancer marker of the present invention characteristic to breast cancer patients can be obtained. Therefore, by detecting / identifying the breast cancer marker of the present invention from a sample such as the nipple discharge fluid of the subject and analyzing the presence pattern of these multiple breast cancer markers of the present invention, it is determined whether or not the subject has developed breast cancer. Estimation is possible.
- the combination of two or more breast cancer markers may be arbitrarily selected from the group consisting of the breast cancer markers of the present invention.
- one or more breast cancer markers of the present invention and one or more breast cancer markers other than the breast cancer marker of the present invention may be detected and measured, and breast cancer may be determined by the same method as described above. Detection of breast cancer markers other than the breast cancer marker of the present invention may be performed by a method known per se according to each breast cancer marker.
- Examples of the sample used for detecting the breast cancer marker of the present invention include a subject's nipple secretion, or a biological sample such as blood (whole blood), serum, plasma, urine, lymph, etc. It is not limited.
- nipple discharge fluid examples include, but are not limited to, a nipple discharge fluid that is naturally secreted from one or both breasts of a subject, a secretion fluid that exudes by breast massage, and a nipple aspirate fluid.
- the sample can be collected non-invasively to the subject, which is excellent in that the burden on the patient is much less.
- the “kit for detecting a breast cancer marker for determining breast cancer” of the present invention includes a reagent for detecting the breast cancer marker of the present invention as a constituent element.
- the “reagent for detecting a breast cancer marker of the present invention” and preferred embodiments and specific examples of the constituents thereof are as described in the above description of the method for detecting a breast cancer marker of the present invention. Moreover, a preferable embodiment such as the concentration of these reagents may be appropriately selected from a concentration range usually used in this field.
- a reagent for detecting the breast cancer marker of the present invention one containing a substance having affinity for the breast cancer marker can be mentioned.
- substances having affinity for the breast cancer marker include antibodies and lectins.
- the kit may comprise a reagent or kit for detecting one kind of breast cancer marker, or may comprise a combination of a plurality of reagents or kits for detecting a plurality of breast cancer markers.
- a combination of a plurality of reagents or kits for detecting a plurality of breast cancer markers in addition to a combination of a plurality of reagents or kits for detecting a plurality of breast cancer markers of the present invention, one type or a plurality of the present invention.
- the reagents included in these kits include reagents usually used in this field, such as buffers, reaction accelerators, sugars, proteins, salts, stabilizers such as surfactants, preservatives, and the like.
- reagents usually used in this field such as buffers, reaction accelerators, sugars, proteins, salts, stabilizers such as surfactants, preservatives, and the like.
- a reagent that does not inhibit the stability of the coexisting reagent or the like and does not inhibit the reaction between the breast cancer marker of the present invention and the antibody (or lectin or the like) may be contained.
- the concentration may be appropriately selected from the concentration range usually used in this field.
- kits may be combined with a standard for preparing a calibration curve used for detecting the breast cancer marker.
- a standard a commercially available standard product or a product manufactured according to a known method may be used.
- Example 1 Breast Cancer Marker Selection
- Sample Pretreatment Each nipple discharge (several ⁇ L) collected from breast cancer patients (11 patients) was treated with 100 ⁇ L of sample stock solution (50 mM ammonium bicarbonate and 0.02% azide). Aqueous solution containing sodium chloride) and centrifuged at 18,000 ⁇ g for 5 minutes at 4 ° C. After the supernatant was collected, the protein concentration was determined by an ultraviolet absorption method using ultraviolet light having a wavelength of 280 nm, and the protein concentration was adjusted to 0.5 mg / mL using a 50 mM aqueous ammonium hydrogen carbonate solution.
- nipple secretions collected from non-breast cancer patients (15 subjects) who were diagnosed as non-breast cancer patients (subjects) who complained of secretory fluid secretion from the nipples as indefinite complaint Processed.
- LC condition first dimension
- HPLC column Acclaim PA2, 300 ⁇ m id x 15 cm reverse phase column (manufactured by Thermo Fisher Scientific Inc. (Dionex))
- Flow rate 6.0 ⁇ L / min
- a Solvent 20 mM ammonium formate aqueous solution, pH 10.0
- B Solvent Acetonitrile Elution: 0 min ⁇ 19 min: Linear gradient from 12% to 20% B solvent, 19 min ⁇ 29 min: linear gradient up to 48% B solvent, 29 minutes ⁇ 34 minutes: wash with 95% B solvent, 34 min ⁇ 75 min: equilibrated with 2% B solvent.
- HPLC column L-column Micro L2-C18, 75 ⁇ m id x 15 cm reversed-phase column (Chemicals Research Institute) Flow rate: 300 nL / min A Solvent: 0.1% formic acid aqueous solution, pH 2.0 B solvent: acetonitrile / 0.1% formic acid Elution: 0 min ⁇ 1 min: linear gradient up to 8% B solvent, 1 min to 20 min: linear gradient up to 20% B solvent, 20 min to 25 min: linear gradient up to 35% B solvent, 25 minutes ⁇ 30 minutes: wash with 95% B solvent, 30 min ⁇ 45 min: equilibrated with 2% B solvent. Column temperature: Room temperature Injection volume: 30 ⁇ L
- Ionization method Electrospray ionization method (ESP method) Measurement ion: Positive ion Spray voltage: 1200V Dry gas: Nitrogen (4 L / min) Ion source temperature: 160 ° C Scanning range: m / z 300 to 1,500 (MS / MS measurement: m / z 50 to 2,200) Precursor ion selection number: 4 ions / mass spectrum Minimum precursor ion intensity: 50,000 counts Precursor ion selection exclusion time: 30 s Precursor ion exclusion valence: 1
- Protein search engine Mascot (Matrix Science Ltd., London, UK)
- Protein search method MS / MS Ion Search Protein Database: Swiss-Prot Animal species classification at protein search: Homo sapiens (human) Post-translational modification at protein search: Carbamidomethyl (Cysteine residue modification) Allowable number of trypsin uncleaved sites: 1 Precursor ion mass tolerance: ⁇ 0.5 Da Product ion mass tolerance: ⁇ 1 Da
- Identification protein analysis software Scaffold (Proteome Software, Inc., Portland, OR, USA)
- proteins specifically detected from breast cancer patient samples were selected as breast cancer marker candidates by the following method.
- Ratio A of the number (n1) of breast cancer patients in which each protein component was detected in the sample among 11 breast cancer patients who were analyzed.
- Ratio B of the number of non-breast cancer patients (n2) in which each protein component was detected in the sample among 15 non-breast cancer patients who were analyzed, and
- Ratio A / Ratio B Ratio C
- Table 1 shows a list of protein components having a ratio C of 2.00 or more among 575 types of protein components detected in (3) above due to space limitations.
- protein components that are suspected to be blood-derived components are excluded, and peptide peaks that are protein components with a ratio C of 2.4 or more and detected in the mass spectrum
- a protein component in which the spectrum count value indicating the abundance of the protein component calculated based on the above is a statistically significant difference between breast cancer patients and non-breast cancer patients (a protein component of p ⁇ 0.05 in the Mann-Whitney U test) ) was selected as a breast cancer marker candidate.
- the selected breast cancer markers and the ratios A, B, and C of each breast cancer marker are shown in Table 2, and the statistical results are shown in FIGS.
- the ratio C in this case describes the same value as the number of n1 breast cancer patients (*).
- carboxypeptidase N subunit 2 (Carboxypeptidase N subunit 2), extracellular matrix protein 1 (Extracellular matrix N protein 1), serum amyloid P component (Serum amyloid P component), nebulin, complement Body component C8 ⁇ chain (Complement component C8 alpha chain), apolipoprotein L1 (Apolipoprotein L1), flavin reductase (Flavin reductase), catalase, carbonic anhydrase 2 (Carbonic anhydrase 2), apolipo Protein CI (Apolipoprotein CI), Nuclear Membrane Porous Glycoprotein 210 (Nuclear pore membrane glycoprotein ⁇ 210), Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase [Cu-Zn]) (Superoxide (dismutase) [Cu-Zn]), Bisphosphoglycerate mutase e) Carbonic anhydrase 1 (Carbonic
- these breast cancer markers were present in high concentrations in the nipple secretions of breast cancer patients compared to the concentrations in the nipple secretions of non-breast cancer patients. Moreover, since these components have not been used as a breast cancer marker, they are extremely promising as a novel breast cancer marker.
- breast cancer and its progress can be determined by detecting these breast cancer markers alone or in combination of two or more.
- the presence pattern of the breast cancer marker of the present invention which is characteristic for breast cancer patients, can be obtained by detecting these breast cancer markers alone or in combination of two or more. Therefore, by detecting and identifying the breast cancer marker of the present invention from a sample such as the nipple secretion of the subject and analyzing the presence pattern of these breast cancer markers, it is possible to estimate whether or not the subject has developed breast cancer. It is expected to be
- the determination method using the breast cancer marker of the present invention enables determination (diagnosis, examination) of breast cancer with higher accuracy.
- the breast cancer marker of the present invention is found, for example, in the nipple secretion, it is possible to determine (diagnose, test) breast cancer noninvasively and simply. As a result, breast cancer diagnosis according to the present invention with less mental and physical distress promotes the breast cancer screening of younger generations and younger breast-feeding women during and after breastfeeding voluntarily. An economic effect is expected by improving the screening rate and reducing breast cancer mortality.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
(1)カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカー。
(2)試料中のカルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から任意に選択される1つ以上の乳癌マーカーを検出し、その結果に基づいて判定する、乳癌の判定方法。
(3)カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカーを検出する試薬を含む、乳癌を判定するために乳癌マーカーを検出するためのキット。
(1)試料の前処理
乳癌患者(11名)から採取したそれぞれの乳頭分泌液(数μL)を、100μL のサンプル保存液(50 mM 炭酸水素アンモニウムと0.02% アジ化ナトリウムを含有する水溶液)に加え、4℃、5分間 18,000 x g で遠心した。上澄みを分取後、280 nm の波長の紫外線を用いた紫外吸収法によりタンパク質濃度を求め、50 mM 炭酸水素アンモニウム水溶液を用いてタンパク質濃度が 0.5 mg/mL となるように調製した。45 mM ジチオトレイトール水溶液を 1.41μL 加えて還元し、タンパク質を変性させるためトリフルオロエタノールを 50% になるよう加え、60 ℃、1時間加熱した。加熱後室温に戻し、100 mM のヨードアセトアミド水溶液を 1.41μL 加えて室温暗環境下において1時間アルキル化を行った。次いで、アルキル化産物から10μLを分取し、90μLの50 mM 炭酸水素アンモニウム水溶液を加えて、トリフルオロエタノールの割合が 5%になるように調整した。更に、100ng/μLのトリプシン(マススペクトロメトリーグレード、Promega Corporation, Madison, WI, USA)の溶液 1.2μL(タンパク質重量の 1/20量のトリプシン含有)を加え 37 ℃ で一晩インキュベートした。得られたトリプシン消化産物(タンパク質換算で約 350 fmol/μL)について、以下の方法で二次元ナノLC-ESI-MS/MS測定を行った。
上記(1)で得られたトリプシン消化産物のうち40μLを、二次元 Nano HPLC system (UltiMate 3000; Thermo Fisher Scientific Inc. (Dionex), Waltham, MA, USA) に装着した Acclaim PA2, 300μm i.d. x 15 cm 逆相カラム (Thermo Fisher Scientific Inc. (Dionex), Waltham, MA, USA) を用いて A 溶媒 20 mM ギ酸アンモニウム水溶液, pH 10.0、B 溶媒 アセトニトリルを用い、75分のグラジエント(12~95% の B 溶媒)で分離し 26 個の画分を得た。それらの画分を 70 ℃ で4時間加熱して溶媒を蒸発させた。次いで各々の画分に 0.1% トリフルオロ酢酸水溶液を 30μL 加えて、分離した成分を溶解させた。次いで、得られた各画分溶液の各全量を、それぞれ L-column Micro L2-C18, 75μm i.d. x 15 cm 逆相カラム((財)化学物質評価研究機構製)を用いて A 溶媒 0.1% ギ酸水溶液、B 溶媒 アセトニトリル/0.1% ギ酸を用い、45分のグラジエント(2~95% の B 溶媒)で分離し、連続的にナノESIイオン源を装着したESI-イオントラップ型質量分析計 (HCTultra; Bruker Daltonik GmbH, Bremen, Germany)でデータ依存的スキャンを用いてオンライン分析した。各試料について、2回のランを行った。
i)LC 条件
(一次元目)
HPLCカラム:Acclaim PA2, 300μm i.d. x 15 cm 逆相カラム (Thermo Fisher Scientific Inc. (Dionex) 製)
流速:6.0μL/分
A 溶媒:20 mM ギ酸アンモニウム水溶液, pH 10.0
B 溶媒:アセトニトリル
溶出: 0分→19 分:12% から 20% B 溶媒までリニアグラジエント、
19 分→29 分:48% B 溶媒までリニアグラジエント、
29 分→34 分:95% B 溶媒で洗浄、
34 分→75 分:2% B 溶媒で平衡化。
(なお、溶出開始後すぐにB溶媒の濃度を上げたので、溶出開始後ほとんど0分で、溶出液のB溶媒の濃度は12%になっている。)
カラム温度:35 ℃
注入量:40μL
分画数:26
HPLCカラム:L-column Micro L2-C18, 75μm i.d. x 15 cm 逆相カラム((財)化学物質評価研究機構製)
流速:300 nL/分
A 溶媒:0.1% ギ酸水溶液, pH 2.0
B 溶媒:アセトニトリル/0.1% ギ酸
溶出: 0分→1 分:8% B 溶媒までリニアグラジエント、
1 分→20 分:20% B 溶媒までリニアグラジエント、
20 分→25 分:35% B 溶媒までリニアグラジエント、
25 分→30 分:95% B 溶媒で洗浄、
30 分→45 分:2% B 溶媒で平衡化。
カラム温度:室温
注入量:30μL
イオン化法:エレクトロスプレーイオン化法 (electrospray ionization 法、ESI 法)
測定イオン:正イオン
スプレー電圧:1200V
ドライガス:窒素(4 L/min)
イオン源温度:160 ℃
走査範囲:m/z 300 ~ 1,500(MS/MS 測定時:m/z 50 ~ 2,200)
プリカーサーイオン選択数:4 イオン/マススペクトル
最小限のプリカーサーイオン強度:50,000 カウント
プリカーサーイオン選択排除時間:30 s
プリカーサーイオン排除価数:1
タンパク質サーチエンジン:Mascot (Matrix Science Ltd., London,UK)
タンパク質サーチ手法:MS/MS Ion Search
タンパク質データベース:Swiss-Prot
タンパク質サーチ時動物種分類:Homo sapiens (human)
タンパク質サーチ時翻訳後修飾設定:Carbamidomethyl (システイン残基修飾)
トリプシン未切断部位許容回数:1
プリカーサーイオン質量許容値:±0.5 Da
プロダクトイオン質量許容値:±1 Da
同定タンパク質解析ソフトウェア:Scaffold(Proteome Software,Inc., Portland, OR, USA)
二次元ナノLC-ESI-MS/MS測定によって、乳癌患者由来試料から350種、非乳癌者由来試料から479種、総計575種のタンパク質成分が検出された。この分析では、特許文献2に記載されたペルオキシレドキシン1は乳癌患者試料及び非乳癌者試料の両方から検出され、更に乳癌患者に特異的な検出ではなかったことを、付記しておく。
上記(3)の結果を基に、
(i)分析を行った乳癌患者11名中の、各タンパク質成分が試料中に検出された乳癌患者数(n1)の割合(比率A)、
(ii)分析を行った非乳癌者15名中の、各タンパク質成分が試料中に検出された非乳癌者数(n2)の割合(比率B)、及び
(iii)比率A/比率B(比率C)
を求めた。
Claims (7)
- カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカー。
- 試料中のカルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から任意に選択される1つ以上の乳癌マーカーを検出し、その結果に基づいて判定する、乳癌の判定方法。
- 試料が乳頭分泌液である、請求項2に記載の方法。
- 試料が血清、血漿、又は全血である、請求項2に記載の方法。
- カルボキシペプチダーゼNサブユニット2、細胞外マトリックスタンパク質1、血清アミロイドP成分、ネブリン、補体成分C8α鎖、アポリポタンパク質L1、フラビンレダクターゼ、カタラーゼ、炭酸脱水酵素2(カルボニックアンヒドラーゼ2)、アポリポタンパク質C-I、核膜孔糖タンパク質210、スーパーオキシドジスムターゼ[Cu-Zn](超酸化物不均化酵素[Cu-Zn])、ビスホスホグリセリン酸ムターゼ、炭酸脱水酵素1(カルボニックアンヒドラーゼ1)、及びペルオキシレドキシン2からなる群から選択される乳癌マーカーを検出する試薬を含む、乳癌を判定するために乳癌マーカーを検出するためのキット。
- 乳癌マーカーを検出する試薬が乳癌マーカーに親和性を有する物質を含むものである、請求項5に記載のキット。
- 乳癌マーカーに親和性を有する物質が抗体である、請求項6に記載のキット。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380041482.9A CN104583777A (zh) | 2012-09-05 | 2013-09-03 | 乳癌的鉴定方法 |
US14/416,984 US20150203892A1 (en) | 2012-09-05 | 2013-09-03 | Method for determining breast cancer |
EP13835821.3A EP2894477A4 (en) | 2012-09-05 | 2013-09-03 | METHOD FOR DETECTION OF BREAST CANCER |
JP2014534354A JP6343560B2 (ja) | 2012-09-05 | 2013-09-03 | 乳癌の判定方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-194804 | 2012-09-05 | ||
JP2012194804 | 2012-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014038524A1 true WO2014038524A1 (ja) | 2014-03-13 |
Family
ID=50237133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/073594 WO2014038524A1 (ja) | 2012-09-05 | 2013-09-03 | 乳癌の判定方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150203892A1 (ja) |
EP (1) | EP2894477A4 (ja) |
JP (1) | JP6343560B2 (ja) |
CN (1) | CN104583777A (ja) |
WO (1) | WO2014038524A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016074084A1 (en) * | 2014-11-12 | 2016-05-19 | Consortium For Clinical Diagnostics | Predictive biomarker(s) of treatment with erb antibodies |
WO2020004244A1 (ja) | 2018-06-26 | 2020-01-02 | 富士フイルム和光純薬株式会社 | 膵臓癌の判定用マーカー |
WO2021095824A1 (ja) | 2019-11-15 | 2021-05-20 | 富士フイルム和光純薬株式会社 | 大腸癌の診断を補助する方法、キット及びバイオマーカー |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017181163A2 (en) * | 2016-04-16 | 2017-10-19 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
CN108132349A (zh) * | 2016-11-30 | 2018-06-08 | 北京大学 | 一种用于癫痫预后评估的生物标志物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002131322A (ja) | 2000-07-26 | 2002-05-09 | Pro Duct Health Inc | 乳管からの物質の同定 |
JP2003503050A (ja) * | 1999-06-30 | 2003-01-28 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なヒトカルボキシペプチダーゼである22012 |
JP2008502891A (ja) | 2004-06-18 | 2008-01-31 | エフ.ホフマン−ラ ロシュ アーゲー | 乳癌のマーカーとしてのタンパク質pdx1の使用 |
JP2010502646A (ja) * | 2006-08-29 | 2010-01-28 | バイオストリーム セラピューティクス インコーポレーティッド | ペプチダーゼ結合部分と結合しペプチダーゼ発現組織及び器官をイメージングする放射性イメージング部分 |
WO2011007764A1 (ja) * | 2009-07-14 | 2011-01-20 | 独立行政法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO114835B1 (ro) * | 1997-03-17 | 1999-07-30 | Ioan Puşcaş | Metodă rapidă de diagnostic al cancerelor |
US6964849B2 (en) * | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
ATE503023T1 (de) * | 2001-06-18 | 2011-04-15 | Rosetta Inpharmatics Llc | Diagnose und prognose von brustkrebspatientinnen |
AU2003217774A1 (en) * | 2002-02-28 | 2003-09-16 | Georgetown University | Method and composition for detection and treatment of breast cancer |
EP1539957A4 (en) * | 2002-09-05 | 2006-10-11 | Garvan Inst Med Res | NEW DIAGNOSTIC AND THERAPY PROCEDURES AND REAGENTS FOR THIS |
GB0616045D0 (en) * | 2006-08-11 | 2006-09-20 | Univ Bristol | Blood cell separation |
WO2008074131A1 (en) * | 2006-12-20 | 2008-06-26 | Mcmaster University | Skin and salivary tests for the detection of sensitivity to oxidative stress based therapies |
US8097423B2 (en) * | 2007-07-30 | 2012-01-17 | Institute Of Virology | MN/CA IX and breast cancer therapy |
US8728744B2 (en) * | 2007-10-26 | 2014-05-20 | The Regents Of The University Of California | Salivary protein biomarkers for human oral cancer |
JP2015155795A (ja) * | 2012-05-21 | 2015-08-27 | 東レ株式会社 | 癌の検出方法 |
-
2013
- 2013-09-03 JP JP2014534354A patent/JP6343560B2/ja not_active Expired - Fee Related
- 2013-09-03 CN CN201380041482.9A patent/CN104583777A/zh active Pending
- 2013-09-03 WO PCT/JP2013/073594 patent/WO2014038524A1/ja active Application Filing
- 2013-09-03 EP EP13835821.3A patent/EP2894477A4/en not_active Withdrawn
- 2013-09-03 US US14/416,984 patent/US20150203892A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003503050A (ja) * | 1999-06-30 | 2003-01-28 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規なヒトカルボキシペプチダーゼである22012 |
JP2002131322A (ja) | 2000-07-26 | 2002-05-09 | Pro Duct Health Inc | 乳管からの物質の同定 |
JP2008502891A (ja) | 2004-06-18 | 2008-01-31 | エフ.ホフマン−ラ ロシュ アーゲー | 乳癌のマーカーとしてのタンパク質pdx1の使用 |
JP2010502646A (ja) * | 2006-08-29 | 2010-01-28 | バイオストリーム セラピューティクス インコーポレーティッド | ペプチダーゼ結合部分と結合しペプチダーゼ発現組織及び器官をイメージングする放射性イメージング部分 |
WO2011007764A1 (ja) * | 2009-07-14 | 2011-01-20 | 独立行政法人産業技術総合研究所 | 肝疾患病態指標糖鎖マーカー |
Non-Patent Citations (3)
Title |
---|
F. MANNELLO ET AL., EXPERT REV. PROTEOMICS, vol. 6, 2009, pages 43 - 60 |
SADAMU KURONO ET AL.: "Nano LC-ESI-IT-MS ni yoru Rinsho Kentai o Mochiita Proteome Kaiseki kara Miete kuru Koto", JSBMS LETT, vol. 36, 10 August 2011 (2011-08-10), pages 39, XP055186888 * |
See also references of EP2894477A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016074084A1 (en) * | 2014-11-12 | 2016-05-19 | Consortium For Clinical Diagnostics | Predictive biomarker(s) of treatment with erb antibodies |
WO2020004244A1 (ja) | 2018-06-26 | 2020-01-02 | 富士フイルム和光純薬株式会社 | 膵臓癌の判定用マーカー |
WO2021095824A1 (ja) | 2019-11-15 | 2021-05-20 | 富士フイルム和光純薬株式会社 | 大腸癌の診断を補助する方法、キット及びバイオマーカー |
Also Published As
Publication number | Publication date |
---|---|
CN104583777A (zh) | 2015-04-29 |
JP6343560B2 (ja) | 2018-06-13 |
EP2894477A1 (en) | 2015-07-15 |
JPWO2014038524A1 (ja) | 2016-08-08 |
US20150203892A1 (en) | 2015-07-23 |
EP2894477A4 (en) | 2016-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020202066A1 (en) | Methods and compositions for detecting pancreatic cancer | |
JP6096813B2 (ja) | 乳癌診断用マルチバイオマーカーセット、その検出方法、及びそれに対する抗体を含む乳癌診断キット | |
AU2013210776B2 (en) | Biomarkers for gastric cancer and uses thereof | |
US8623667B2 (en) | Method for diagnosing cancer using lectin | |
JP6343560B2 (ja) | 乳癌の判定方法 | |
CN102687011B (zh) | 癌症生物标志物及其应用 | |
KR20200020927A (ko) | 대장암을 검출하기 위한 바이오마커 | |
EP4045912A1 (en) | Apparatuses and methods for detection of pancreatic cancer | |
JP6336957B2 (ja) | 乳癌の判定法 | |
US20140236166A1 (en) | Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts | |
EP4027143A1 (en) | Method for detecting particulate substance using immunochromatography, and kit for same | |
JP5867834B2 (ja) | 肺癌マーカー補体C3dg分子及び肺癌マーカーの分析方法 | |
CN112543871A (zh) | 胰腺癌判断用的标记物 | |
KR101219516B1 (ko) | 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 | |
JP5429725B1 (ja) | 前立腺癌の進行度の評価方法、前立腺癌の検出方法、および検査キット | |
JP2017090102A (ja) | 浸潤性乳癌の判定法 | |
JP2017090103A (ja) | 非浸潤性乳癌の判定法 | |
JP6145650B2 (ja) | 卵巣癌マーカー及び卵巣癌検出方法 | |
JP7336097B2 (ja) | 乳がんに関するペプチドマーカー | |
JP2017198509A (ja) | 大腸癌マーカー | |
KR101819939B1 (ko) | 유방암 진단용 단백질 마커 베타-투 마이크로글로불린 및 이를 검출하는 방법 | |
KR101912377B1 (ko) | 폐암감별진단용 바이오마커 및 이를 이용한 폐암감별진단용 정보제공 방법 | |
You | Discovery of novel potential protein diagnostic biomarkers for Prostate Cancer in serum and tears | |
CN116802497A (zh) | 乳腺癌的诊断辅助方法及乳腺癌检查试剂盒 | |
WO2016208041A1 (ja) | 卵巣癌マーカー及び卵巣癌検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13835821 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14416984 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014534354 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013835821 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |